Vertaling van "1 duration " (Frans → Nederlands) :

TERMINOLOGIE

1) ambulant - 2) ambulatoire | 1) qui se déplace ou s'étend - 2) capable de se déplacer/laissant la possibilité de se déplacer
ambulant | in staat om te lopen

1) basal - 2) basique | 1) qui concerne la base d'un organe - 2) se rapportant à une base
basaal | met betrekking tot een stof die zout vormt

1) base - 2) base | 1) partie inférieure d'un organe - 2) base | alcalin
base | stof die zout vormt

1) correctif - 2) correction | 1) substance ajoutée à un médicament pour en modifier l'action - 2) de la vue
correctie | verbetering

1) auriculaire - 2) auriculaire | 1) qui se rapporte à l'oreille - 2) qui se rapporte à une oreillette | à une auricule
auriculair | met betrekking tot het oor

1) auditif - 2) auriculaire | 1) qui se rapporte à l'ouie - 2) de l'oreille
auraal | met betrekking tot een voorbode

1) anabolique - 2) anabolisant | 1) qui se rapporte à l'anabolisme - 2) qui renforce l'anabolisme
anabool | weefselopbouwend

1) asystolie - 2) asystole | 1) insuffisance cardiaque globale - 2) arrêt de la fonction pompe du coeur
asystolie | hartstilstand

1) atopique - 2) atopie | 1) allergique - 2) réaction violentes aux allergènes
atopisch | met betrekking tot een vorm van overgevoeligheid

1) décongestif (a et sm) - 2) décongestionnant | 1) contre l'obstruction - 2) (médicament) qui dégage le nez
decongestivum | middel dat zwelling vermindert

IN-CONTEXT TRANSLATIONS

[1] Duration of Lactation and Risk Factors for Maternal Cardiovascular Disease – Schwarz et al.- Gynecol.
Duration of Lactation and Risk Factors for Maternal Cardiovascular Disease – Schwarz et al.- Obstet Gynecol.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

13. Guillemot D, Carbon C, Balkan B et al : Low dosage and long treatment duration of beta-lactam : risk factor for carriage of penicillin-resisiant Streptococcus pneumonies.
13. Guillemot D, Carbon C, Balkan B et al: Low dosage and long treatment duration of beta-lactam: risk factor for carriage of penicillin-resisiant Streptococcus pneumonies.

Les critères d’évaluation secondaires étaient le délai de réponse tumorale (Time to Tumor Response, TTR), la durée de réponse (Duration of Response, DR), le taux de contrôle de la maladie (Disease Control Rate, DCR), la survie sans progression (Progression-Free Survival, PFS) et la survie globale (Overall Survival, OS).
De secundaire eindpunten omvatten tijd tot tumorrespons (Time to Tumour Response, TTR), duur van respons (Duration of Response, DR), percentage ziektecontrole (Disease Control Rate, DCR), progressievrije overleving (Progression-Free Survival, PFS), en algehele overleving (Overall Survival, OS).

Unit cost: €2.53 Costs of interventions in current practice based on Dutch empirical data Cost calculations of interventions in increased implementation program based on Dutch practice guidelines and (for the duration of NRT and Buproprion) on international trials (Cochrane meta-analysis) Costs of smoking-related diseases were taken into account, estimates based on Dutch cost-ofillness study that allocated total direct health care costs to diseases.
Unit cost: €2.53 Costs of interventions in current practice based on Dutch empirical data Cost calculations of interventions in increased implementation program based on Dutch practice guidelines and (for the duration of NRT and bupropion) on international trials (Cochrane meta-analysis) Costs of smoking-related diseases were taken into account, estimates based on Dutch cost-ofillness study that allocated total direct health care costs to diseases.

Buproprion is assumed to be prescribed in two 4-week packs, given that the recommended duration of treatment is 7-9 weeks.
Bupropion is assumed to be prescribed in two 4-week packs, given that the recommended duration of treatment is 7-9 weeks.

[3] Thomas Harder1 et al. Duration of Breastfeeding and Risk of Overweight: A Meta-Analysis.
[3] Thomas Harder1 et al. Duration of Breastfeeding and Risk of Overweight: A Meta-Analysis.

Design Population Intervention n Duration Outcomes Results
Design Population Intervention N/n Duration Outcomes Results

Arch Intern Med 2006; 166:357-65. Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial.

(1) La publication de référence suivante de W. Kissling est confirmée par une étude plus récente : W. Kissling, Duration of Neuroleptic Maintenance Treatment, in W. Kissling Guidelines for Neuroleptic Relapse Prevention, Springer Verlag Berlin Heidelberg, 1991, pp 95-107 (2) Même référence que pour 1.
(1) De volgende referentie publicatie van W. Kissling is bevestigd door recenter onderzoek: W. Kissling, Duration of Neuroleptic Maintenance Treatment, in W. Kissling Guidelines for Neuroleptic Relapse Prevention, Springer-Verlag Berlin Heidelberg, 1991, pp95-107 (2) Zelfde referentie als 1.